Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

First-line venetoclax-based regimens versus chemoimmunotherapy in chronic lymphocytic leukemia: A real-world analysis from the brazilian CLL registry

View Full Paper
Ask AI
Bookmark
Share

Authors

SNSamir NabhanMAMilton AranhaDFDanielle De Farias

Discussion

Loading...

Member takes

Overview

Retrospective analysis finds better time to next treatment with venetoclax over chemoimmunotherapy in patients with chronic lymphocytic leukemia.

Key Points

  • Overall survival was similar with both venetoclax-based regimens and chemoimmunotherapy, each at 87%.
  • Three-year time to next treatment was significantly higher with venetoclax-based regimens at 80% compared to 58% for chemoimmunotherapy (P=0.006).
  • Patients treated with venetoclax-obinutuzumab showed favorable outcomes in this evaluation of the Brazilian CLL Registry.
  • Real-world data confirmed the effectiveness of venetoclax as a first-line therapy, even in patients at high risk.

Cite This Study

Nabhan et al. (2025) studied this question.

synapsesocial.com/papers/69362f714fa91c937236e1cbhttps://doi.org/10.1182/blood-2025-7413
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Clinical experience and safety of venetoclax in the treatment of patients with chronic lymphocytic leukemia in second and subsequent lines of therapy: Real-world data fron hemato-oncology centers  of slovakia2025
  2. 2Real‐World Safety and Efficacy of Venetoclax in Chronic Lymphocytic Leukemia: A Single‐Center Comparative Analysis With Randomized Clinical Trials2025 · 1 citations
  3. 3Real-world survival outcomes with first-line venetoclax therapy in AML2025
  4. 4Real-world treatment patterns and patient characteristics of venetoclax combination time-limited therapy for chronic lymphocytic leukemia2025
  5. 5Venetoclax and obinutuzumab in first-line treatment of unfit patients with CLL – real-life data analysis of the Polish Adult leukemia group2025 · 3 citations